PRNewswire

HERZLIYA, Israel, June 3, 2024 /PRNewswire/ -- Vintage Investment Partners, a global venture capital platform with $4 billion under management, is excited to announce the promotion of Shira Eting to Partner, and the appointment of Erez Mor as Chief Information Security Officer.  

Shira joined Vintage in 2019, after a successful tenure at McKinsey & Co.... (continue reading...)

Award-winning firm hires skilled attorney with 20+ years experience

DURHAM, N.C., June 3, 2024 /PRNewswire/ -- The Law Offices of James Scott Farrin continues to add knowledge and experience to its personal injury practice as it welcomes Andréa Morelos, an attorney who has spent the last two decades advocating for those in need. She joins a firm that has provided legal representation to over 65,000 injured people since 1997 – in 2023 alone, the firm recovered over... (continue reading...)

The binational company brought successful initiatives in water resources management to the international event

FOZ DO IGUAÇU, Brazil, June 3, 2024 /PRNewswire/ -- The 10th World Water Forum, held in Bali, Indonesia, concluded on May 25th with the launch of the Ministerial Declaration on "Water for Shared Prosperity". Delegations from 106 countries and 27 international organizations participated in the meeting. A delegation from Itaipu Binacional attended the event,... (continue reading...)

OCEANSIDE, Calif., June 3, 2024 /PRNewswire/ -- BRIXTON today announced the appointment of Brian White, an industry veteran, to SVP US Wholesale. Most recently, Brian served as the SVP of Global Sales for Herschel Supply after serving as the VP of Sales for Nixon and managing his own agency, including brands like Ride, Hurley, Globe, and DaKine. Brian brings a wealth of experience and a proven track record of success working in action sports and fashion... (continue reading...)

Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data

CHICAGO, June 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion... (continue reading...)